ABSTRACT
Introduction Progress achieved by long-lasting insecticidal nets (LLINs) against malaria is threatened by the widespread selection of pyrethroid resistance among vector populations. LLINs with non-pyrethroid insecticides are urgently needed. This study aims to assess the durability of three novel dual active ingredient LLINs and to parameterise a mathematical model to predict epidemiological outcomes of these products for malaria vector control.
Methods A WHO Phase 3 active ingredients and textile durability study will be carried out within a cluster randomised controlled trial in Misungwi district in 40 clusters. The following treatments will be evaluated; 1/ Interceptor G2® combining chlorfenapyr and a pyrethroid alpha-cypermethrin, 2/ Royal Guard® treated with pyriproxyfen and alpha-cypermethrin and 3/ Olyset™ Plus which incorporates a synergist piperonyl butoxide and the pyrethroid permethrin, and 4/ a reference standard pyrethroid-only LLIN (Interceptor®). 750 nets will be followed in 5 clusters per intervention arm at 6, 12, 24 and 36 months post distribution for survivorship and hole index assessment. A second cohort of 1950 nets per each type will be identified in 10 clusters, of which 30 LLINs will be withdrawn for bio-efficacy and chemical analysis every 6 months up to 36 months and another 30 collected for an experimental hut trial study every year. Bio-efficacy will be assessed using cone bioassays and tunnel tests against susceptible and resistant laboratory strains of Anopheles gambiae sensu stricto. Efficacy of field collected nets will be compared in six experimental huts. The main outcomes will be Anopheles mortality up to 72 hours post exposure, blood feeding and egg maturation using ovary dissection to assess impact on fecundity.
Ethics and dissemination Ethical approval was received from the Tanzanian ethics review committee as well as from each institution. Study findings will be disseminated via reports and presentations to national and international stakeholders, conferences, and peer-reviewed publications.
Trial registration number NCT03554616
Strengths of this study
This is the first study assessing the durability of these novel dual-A.I. LLINs over three years alongside a cluster randomised controlled trial (cRCT).
The study will support the development of bio-efficacy and physical durability criteria of performance for the partner A.I. in relation to the cRCT efficacy outcomes and refine preferred product characteristics developed by the WHO.
An experimental hut trial done in the vicinity of the cRCT, with similar vector population characteristics and using nets sampled from the main trial will allow us to understand the impact of field conditions, wear-and-tear and insecticidal deterioration on the efficacy of the dual-A.I. LLINs on entomological outcomes and relate these to the cRCT epidemiological and entomological outcomes.
All other products falling under these novel dual-A.I. LLINs classes will be assessed according to those criteria alongside non-inferiority studies in experimental huts and modelling of these data.
Limitations of this study Potential limitations include 1/ the net loss of follow up used to calculate sample size, which was taken from another study site and might differ in Misungwi, and 2/ the experimental hut site is situated in the northern section of the cRCT study area and may not represent vector species composition of the southern section of the cRCT.
- Bio-efficacy
- textile durability
- malaria vectors
- insecticide resistance
- Royal Guard
- Interceptor G2
- Olyset Plus
- Interceptor
- Tanzania
- experimental hut trial
- long-lasting insecticidal net
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03554616
Clinical Protocols
https://bmjopen.bmj.com/content/11/3/e046664
Funding Statement
This project is funded by the Bill and Melinda Gates Foundation through the Innovative Vector Control Consortium and under the global health trial, a jointly funded initiative from The Department of Health and Social Care, the Department for International Development, the Medical Research Council and the Wellcome Trust (Grant Ref: MR/R006040/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol has received ethical approval from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR), Kilimanjaro Christian Medical University College (KCMUCO), and the London School of Hygiene and Tropical Medicine (LSHTM).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
LAM- louisa.messenger{at}lshtm.ac.uk, FWM – fwmosha{at}gmail.com, EL- Eliud.Lukole{at}lshtm.ac.uk, JFM - jfmosha{at}yahoo.com, TSC- thomas.churcher{at}imperial.ac.uk, ESS - e.sherrard-smith{at}imperial.ac.uk, MK-Manisha.Kulkarni{at}uottawa.ca, AM - amanjurano{at}yahoo.com, NP – natacha.protopopoff{at}lshtm.ac.uk and MR - mark.rowland{at}lshtm.ac.uk
Funding. This project is funded by the Bill and Melinda Gates Foundation through the Innovative Vector Control Consortium and under the global health trial, a jointly funded initiative from The Department of Health and Social Care, the Department for International Development, the Medical Research Council and the Wellcome Trust (Grant Ref: MR/R006040/1).
Data Availability
Not applicable.
